NO20081654L - Stabiliserte GLP-1-analoger - Google Patents

Stabiliserte GLP-1-analoger

Info

Publication number: NO20081654L
Authority: NO; Norway
Prior art keywords: amino acid; glp; analogs; base sequence; side groups
Prior art date: 2005-09-08

Application number

NO20081654A

Other languages

English (en)

Norwegian (no)

Inventor

William W Bachovchin

David George Sanford

Original Assignee

Tufts College

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-08

Filing date

2008-04-03

Publication date

2008-04-03

2008-04-03 Application filed by Tufts College filed Critical Tufts College

2008-04-03 Publication of NO20081654L publication Critical patent/NO20081654L/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
150000001413 amino acids Chemical class 0.000 abstract 9
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 3
102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 3
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)

NO20081654A 2005-09-08 2008-04-03 Stabiliserte GLP-1-analoger NO20081654L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71532205P	2005-09-08	2005-09-08
PCT/US2006/034685 WO2007030519A2 (fr)	2005-09-08	2006-09-07	Analogues de glp-1 stabilises

Publications (1)

Publication Number	Publication Date
NO20081654L true NO20081654L (no)	2008-04-03

Family

ID=37836409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081654A NO20081654L (no)	2005-09-08	2008-04-03	Stabiliserte GLP-1-analoger

Country Status (11)

Country	Link
US (1)	US8318668B2 (fr)
EP (2)	EP1940438A4 (fr)
JP (1)	JP2009507844A (fr)
KR (1)	KR20080052649A (fr)
CN (1)	CN101262874A (fr)
AU (1)	AU2006287562B2 (fr)
BR (1)	BRPI0615573A2 (fr)
CA (1)	CA2621699A1 (fr)
IL (1)	IL189996A0 (fr)
NO (1)	NO20081654L (fr)
WO (1)	WO2007030519A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7259234B2 (en) *	2003-05-15	2007-08-21	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics
US20110245173A1 (en) *	2008-06-03	2011-10-06	Bachovchin William W	Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction
JP6121323B2 (ja)	2010-05-13	2017-05-10	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP5819946B2 (ja) *	2010-05-17	2015-11-24	ベータファーマシューティカルズカンパニーリミテッド	新規のグルカゴン様ペプチド類似体、組成物、および使用方法
EP2588126A4 (fr)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	Promédicaments peptidiques à base d'amides de la superfamille du glucagon
CN102363633B (zh) *	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
EP2630965A1 (fr) *	2012-02-24	2013-08-28	Curatis Pharma GmbH	Polypeptide pour la protection contre la neurodégénérescence chez les patients souffrant de la sclérose latérale amyotrophique
CN105934257B (zh)	2013-12-06	2020-10-09	韩捷	用于含氮和羟基的药物的生物可逆引入基团
JP5910901B1 (ja) *	2015-03-27	2016-04-27	株式会社東洋新薬	Ｇｌｐ−１分泌促進剤
TWI726889B (zh) *	2015-06-10	2021-05-11	英商梅迪繆思有限公司	蛋白酶抗性之脂化肽
ES2925678T3 (es)	2018-04-05	2022-10-19	Sun Pharmaceutical Ind Ltd	Nuevos análogos de GLP-1
EP3875476A4 (fr) *	2018-10-30	2022-08-24	Jianning Liu	Polypeptide glp-1 doté d'une activité d'agoniste du récepteur de glp-1 et son application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
EP0636032A1 (fr)	1992-03-25	1995-02-01	Mallinckrodt Medical, Inc.	Procede pour detecter et localiser de fa on peroperatoire des tissus tumoraux
CA2150574A1 (fr)	1993-01-06	1994-07-21	Shalaby W. Shalaby	Conjugues moleculaires ioniques de polyesters degradables et de polypeptides bioactifs
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
CA2455963C (fr)	2001-07-31	2017-07-04	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Analogues de peptides glp-1, exendine-4 et ses utilisations
JP2005508895A (ja) *	2001-08-28	2005-04-07	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１および基礎インスリンの予備混合物
KR20040054729A (ko) *	2001-10-18	2004-06-25	브리스톨-마이어스 스큅 컴퍼니	인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US7238671B2 (en) *	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7259234B2 (en) *	2003-05-15	2007-08-21	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics

2006
- 2006-09-07 JP JP2008530161A patent/JP2009507844A/ja not_active Ceased
- 2006-09-07 CN CNA2006800331050A patent/CN101262874A/zh active Pending
- 2006-09-07 AU AU2006287562A patent/AU2006287562B2/en not_active Ceased
- 2006-09-07 KR KR1020087008178A patent/KR20080052649A/ko not_active Ceased
- 2006-09-07 CA CA002621699A patent/CA2621699A1/fr not_active Abandoned
- 2006-09-07 BR BRPI0615573-1A patent/BRPI0615573A2/pt not_active Application Discontinuation
- 2006-09-07 EP EP06814219A patent/EP1940438A4/fr not_active Withdrawn
- 2006-09-07 EP EP11194831A patent/EP2497781A1/fr not_active Withdrawn
- 2006-09-07 WO PCT/US2006/034685 patent/WO2007030519A2/fr not_active Ceased
- 2006-09-07 US US12/066,324 patent/US8318668B2/en active Active
2008
- 2008-03-06 IL IL189996A patent/IL189996A0/en unknown
- 2008-04-03 NO NO20081654A patent/NO20081654L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2009507844A (ja)	2009-02-26
EP1940438A4 (fr)	2009-10-21
CN101262874A (zh)	2008-09-10
US8318668B2 (en)	2012-11-27
BRPI0615573A2 (pt)	2011-05-24
KR20080052649A (ko)	2008-06-11
US20090306338A1 (en)	2009-12-10
WO2007030519A3 (fr)	2007-11-29
CA2621699A1 (fr)	2007-03-15
EP2497781A1 (fr)	2012-09-12
AU2006287562A1 (en)	2007-03-15
AU2006287562B2 (en)	2012-05-10
EP1940438A2 (fr)	2008-07-09
WO2007030519A2 (fr)	2007-03-15
IL189996A0 (en)	2008-08-07

Publication	Publication Date	Title
NO20081654L (no)	2008-04-03	Stabiliserte GLP-1-analoger
SA521430398B1 (ar)	2024-05-14	Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
DK1877435T3 (da)	2011-06-06	Glucagon-lignende peptid 2 (GLP-2)-analoger
HRP20090245T1 (en)	2009-07-31	Pyy agonists and uses thereof
CY1110397T1 (el)	2015-04-29	Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης
PE20130615A1 (es)	2013-07-01	Polipeptidos del receptor de activina variante y uso de los mismos
DE602005020165D1 (de)	2010-05-06	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
EA200901108A1 (ru)	2010-02-26	Соагонисты глюкагоновых/glp-1-рецепторов
RU2010147076A (ru)	2012-05-27	Аналоги инсулина специфичные к изоформам
EA201170878A1 (ru)	2012-01-30	Полипептиды с ксиланазной активностью
NO20061026L (no)	2006-03-02	Nye insulinderivater
WO2007115837B1 (fr)	2008-03-27	Combinaison d'une protéine de fusion à anticorps anti-domaine ed-b de fibronectine et à il-2, et de gemcitabine
DK2231860T3 (da)	2011-12-05	Polypeptid afledt protein A og i stand til at binde PDGF
PE20120358A1 (es)	2012-04-26	Mutantes fgf21 y usos de los mismos
MY206268A (en)	2024-12-06	Modified s1 subunit of the coronavirus spike protein
MXPA06010347A (es)	2007-06-19	Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
MX2019013801A (es)	2020-01-30	Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
WO2011038900A3 (fr)	2011-06-23	Analogues peptidiques de glucagon pour une thérapie du diabète
BRPI0715331B8 (pt)	2021-05-25	polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
MX2021013702A (es)	2021-12-10	Subunidad s2 modificada de la proteina de espicula de coronavirus.
MX2015016560A (es)	2017-06-01	Proteina analgesica aislada de la secrecion de la rana trachycephalous venulosus.
NO20083576L (no)	2008-12-10	Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
EP1796707A4 (fr)	2009-09-09	Peptides ciblant selectivement le systeme cardio-vasculaire et conjugues et procedes associes
DE602007006493D1 (de)	2010-06-24	Peptide mit proliferationshemmender wirkung
DE602005025989D1 (de)	2011-03-03	Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden

Legal Events

Date	Code	Title	Description
2013-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application